Vireo Growth Inc Stock Price, News & Analysis

Vireo Growth (OTCQX: VREOF) and Verano Holdings (OTCQX: VRNOF) announced on October 29, 2025 a comprehensive settlement resolving all outstanding litigation between them pending before the Supreme Court of British Columbia.

The settlement, approved by both Boards, provides Vireo with approximately US$10 million in value comprised of certain real estate assets plus US$1 million in cash. The companies said the resolution ends a complex legal chapter and allows both to focus on their strategic priorities and delivering long-term shareholder value.

Vireo Growth (OTCQX: VREOF) closed acquisition of approximately $91,000,000 in senior secured convertible notes of Schwazze (value as of Oct 10, 2025) for total consideration of about $62 million. Vireo issued ~114,807,815 subordinate voting shares to prior noteholders and will assume holders’ rights under the notes, which mature Dec 2026, carry 13.0% interest and are currently in default.

Vireo entered a Restructuring Support Agreement to effect an Asset Sale transferring a majority of Schwazze’s assets (63 dispensaries, 10 manufacturing sites) to a NewCo majority-owned by Vireo, funded in part by up to $62 million of committed financing; remaining Schwazze assets would be wound down. Transactions are subject to closing conditions and regulatory approvals.

Vireo Growth (OTCQX: VREOF) entered definitive agreements on Oct 2, 2025 to acquire ~86% of the outstanding senior secured convertible notes of U.S. multi-state cannabis operator Medicine Man Technologies (dba Schwazze).

The Notes will be purchased at a price substantially below par for total consideration of ~$62 million payable in subordinate voting shares of Vireo at a deemed price of $0.54 per share. The transaction is expected to close later this month and is subject to customary closing conditions, including required approvals.

Vireo Growth (OTCQX: VREOF) has launched adult-use cannabis sales across all eight Green Goods® dispensaries in Minnesota, marking a significant expansion from its existing medical cannabis operations. The company, which has served Minnesota's medical market since 2014, made its first adult-use sale on September 16, 2025, in downtown Minneapolis.

With Minnesota's population of 5.7 million, Vireo expects strong organic revenue growth from this market expansion. The company offers a comprehensive product line including flower, pre-rolls, edibles, and beverages across locations in Minneapolis, Blaine, Bloomington, Burnsville, Duluth, Moorhead, Rochester, and Woodbury.

Vireo Growth (OTCQX:VREOF) has issued a statement in response to a request from the Canadian Investment Regulatory Organization (CIRO) regarding recent market activity. The company confirmed that its management is unaware of any material changes in operations that could explain the recent increase in market activity.

The company included standard forward-looking statements disclaimer, noting that future events may differ from current expectations due to various risks and uncertainties.

Vireo Growth Inc. (OTCQX: VREOF) reported strong Q2 2025 financial results, with GAAP revenue reaching $48.1 million, a 91.4% increase year-over-year. The company completed three significant merger acquisitions in Utah, Missouri, and Nevada, expanding operations to six states. Key financial metrics include Adjusted EBITDA of $13.3 million and pro forma revenue of $90.7 million.

Notably, Vireo secured a $153 million refinancing, comprising a $120 million term loan at 8.3% interest and a $33 million second lien term loan with a $50 million accordion feature. This refinancing is expected to reduce annual interest expenses by over $10 million and has strengthened the company's balance sheet with over $100 million in cash.

Vireo Growth (OTCQX: VREOF) has scheduled its second quarter 2025 financial results release for August 13, 2025, before market opening. The company will host a conference call with investors on the same day at 8:30 a.m. ET to discuss the quarterly performance.

Investors can join the call by dialing 1-800-715-9871 (US/Canada toll-free) or 1-646-307-1963 (International) with conference ID 3718174. A live webcast will be available through the company's Investor Relations website.

Vireo Growth (OTCQX:VREOF) has announced the retirement of its US$10 million convertible note that was due November 1, 2024. The company has simultaneously issued a new US$10 million convertible note on July 7, 2025, as part of a larger refinancing initiative.

The transaction is classified as a "related party transaction" under MI 61-101, as the lender is considered a related party to Vireo. However, the transaction is exempt from formal valuation and minority shareholder approval requirements since the value does not exceed 25% of Vireo's market capitalization.

Vireo Growth (OTCQX:VREOF) has successfully completed a major debt refinancing and expansion of its credit facilities. The company secured a $120 million self-syndicated first lien term loan at 8.3% interest rate and a $33 million second lien term loan with a $50 million accordion feature.

The total $153 million financing package is expected to generate over $10 million in annual interest savings and provides the company with more than $100 million in cash. The refinancing consolidates debt assumed from recent mergers and optimizes the company's capital structure. Both facilities have three-year terms and can be prepaid without penalties.